Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Twelves

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 14, 2002
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trialsC Twelves,
Oncology (Williston Park, N.Y.)|August 12, 1999
UFT plus calcium folinate/irinotecan in colorectal cancerC Twelves
The Oncologist|October 5, 2001
Vision of the future: capecitabineC Twelves
Anticancer Research|January 30, 2003
The rational development of capecitabine from the laboratory to the clinicG Pentheroudakis, C Twelves
Expert Opinion on Pharmacotherapy|October 5, 2001
Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?R Jones, C Twelves
Breast Cancer (Dove Medical Press)|December 25, 2013
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancerJ Menis, C Twelves
BMJ (Clinical Research Ed.)|October 12, 1996
Advertisement for toremifene. Playing on women's fears is unethicalC Twelves, A Harnett
Seminars in Oncology|October 26, 2000
Rational development of capecitabineC Twelves, A Anthoney
The New England Journal of Medicine|November 16, 1995
Doxorubicin-induced cardiotoxicityL Paz-Ares, N Dobbs, C Twelves
Cancer Chemotherapy and Pharmacology|January 1, 1991
Acute reversible neurological deficit following intrathecal chemotherapyH Dunkelman, H M Earl, C Twelves
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|February 14, 2002
Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trialsC Twelves,
Oncology (Williston Park, N.Y.)|August 12, 1999
UFT plus calcium folinate/irinotecan in colorectal cancerC Twelves
The Oncologist|October 5, 2001
Vision of the future: capecitabineC Twelves
Anticancer Research|January 30, 2003
The rational development of capecitabine from the laboratory to the clinicG Pentheroudakis, C Twelves
Expert Opinion on Pharmacotherapy|October 5, 2001
Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?R Jones, C Twelves
Breast Cancer (Dove Medical Press)|December 25, 2013
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancerJ Menis, C Twelves
BMJ (Clinical Research Ed.)|October 12, 1996
Advertisement for toremifene. Playing on women's fears is unethicalC Twelves, A Harnett
Seminars in Oncology|October 26, 2000
Rational development of capecitabineC Twelves, A Anthoney
The New England Journal of Medicine|November 16, 1995
Doxorubicin-induced cardiotoxicityL Paz-Ares, N Dobbs, C Twelves
Cancer Chemotherapy and Pharmacology|January 1, 1991
Acute reversible neurological deficit following intrathecal chemotherapyH Dunkelman, H M Earl, C Twelves
Pageof 8